Our results suggest that rosiglitazone may play an atheroprotective role via its beneficial effects on gelatinases (MMP-2 and −9) throughout inflammatory process particularly in the high cardiovascular risk population of patients with diabetes mellitus. This evidence concerns the gene MMP2 and diabetes mellitus.